Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00615628 · ClinicalTrials.gov registry record
Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18:
A clinical trial, sponsored by State University of New York - Upstate Medical University.
- Terminated
- Registry status
- 8
- Enrollment target
NCT00615628: Clinical Trial study, sponsored by State University of New York - Upstate Medical University.
NCT00615628 is a clinical trial that was terminated before completion, run by State University of New York - Upstate Medical University. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00615628 was terminated before completion, sponsored by State University of New York - Upstate Medical University.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
Researchers have previously demonstrated loss of heterozygosity in a region on chromosome 18q, associated with osteogenic sarcomas in bone affected by Paget's disease. The loci used in this study are specifically described by those authors as showing loss of heterozygosity in 6 of 7 affected families.
Primary Outcome
A loss of heterozygosity of a proposed tumor suppressor gene on chromosome 18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2002-04 |
| Est. Completion | 2009-12 |
Why NCT00615628 stopped before completion
NCT00615628 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00615628 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00615628 about?
NCT00615628 is a clinical study titled "Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18:". Researchers have previously demonstrated loss of heterozygosity in a region on chromosome 18q, associated with osteogenic sarcomas in bone affected by Paget's disease. The loci used in this study are specifically described by those authors as showing loss of heterozygosity in 6 of 7 affected familie...
What is the current status of trial NCT00615628?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2002-04. Estimated completion is 2009-12.
Who is sponsoring clinical trial NCT00615628?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia